New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ustekinumab 45mg;   - solution for injection - 45 mg - active: ustekinumab 45mg   excipient: histidine as hydrochloride polysorbate 80 sucrose water for injection - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ustekinumab 90mg;   - solution for injection - 90 mg - active: ustekinumab 90mg   excipient: histidine as histidine hydrochloride polysorbate 80 sucrose water for injection - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 100ug (plus a 3% manufacturing overage); levothyroxine sodium 100ug (plus a 9% manufacturing overage) - tablet - 100 mcg - active: levothyroxine sodium 100ug (plus a 3% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake active: levothyroxine sodium 100ug (plus a 9% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 112ug (plus a 3% manufacturing overage); levothyroxine sodium 112ug (plus a 9% manufacturing overage) - tablet - 112 mcg - active: levothyroxine sodium 112ug (plus a 3% manufacturing overage) excipient: acacia d&c red lake blend #9570 lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 112ug (plus a 9% manufacturing overage) excipient: acacia d&c red lake blend #9570 lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 125ug (plus a 3% manufacturing overage); levothyroxine sodium 125ug (plus a 9% manufacturing overage) - tablet - 125 mcg - active: levothyroxine sodium 125ug (plus a 3% manufacturing overage) excipient: acacia brown lake blend lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 125ug (plus a 9% manufacturing overage) excipient: acacia brown lake blend lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 137ug (plus a 9% manufacturing overage); levothyroxine sodium 137ug (plus a 3% manufacturing overage) - tablet - 137 mcg - active: levothyroxine sodium 137ug (plus a 9% manufacturing overage) excipient: acacia brilliant blue fcf lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 137ug (plus a 3% manufacturing overage) excipient: acacia brilliant blue fcf lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 150ug (plus a 9% manufacturing overage); levothyroxine sodium 150ug (plus a 2% manufacturing overage) - tablet - 150 mcg - active: levothyroxine sodium 150ug (plus a 9% manufacturing overage) excipient: acacia indigo carmine lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 150ug (plus a 2% manufacturing overage) excipient: acacia indigo carmine lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 175ug (plus a 9% manufacturing overage); levothyroxine sodium 175ug (plus a 2% manufacturing overage) - tablet - 175 mcg - active: levothyroxine sodium 175ug (plus a 9% manufacturing overage) excipient: acacia brilliant blue fcf d&c red lake blend #9570 lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 175ug (plus a 2% manufacturing overage) excipient: acacia brilliant blue fcf d&c red lake blend #9570 lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 200ug (plus a 9% manufacturing overage); levothyroxine sodium 200ug (plus a 2% manufacturing overage) - tablet - 200 mcg - active: levothyroxine sodium 200ug (plus a 9% manufacturing overage) excipient: acacia allura red ac lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 200ug (plus a 2% manufacturing overage) excipient: acacia allura red ac lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 25ug (plus a 5% manufacturing overage); levothyroxine sodium 25ug (plus a 9% manufacturing overage); levothyroxine sodium 25ug (plus a 4% manufacturing overage) - tablet - 25 mcg - active: levothyroxine sodium 25ug (plus a 5% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc sucrose sunset yellow aluminium lake active: levothyroxine sodium 25ug (plus a 9% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc sucrose sunset yellow aluminium lake active: levothyroxine sodium 25ug (plus a 4% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc sucrose sunset yellow aluminium lake - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.